Immunoregulatory compounds and derivatives and methods of treating diseases therewith

The compound according to claim 1, 5-(4-carboxymethyl-phenylazo)-2-hydroxy-benzoic acid.

The compound according to claim 1, 5-[4-(1-carboxy-ethyl)-phenylazo]-2-hydroxy-benzoic acid.

A compound having the following structure:

• where R1, R3, R4, and R5 are independently hydrogen or C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof.

A compound having the following structure:

• where R1 is C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof.

5-(4-carboxymethyl phenylazo)-2-hydroxy-benzoic acid, or an ester or pharmacologically acceptable salt thereof.

5-[(4-(1-carboxy ethyl)-phenylazo]-2-hydroxy-benzoic acid, or an ester or pharmacologically acceptable salt thereof.

A pharmaceutical composition comprising an amount effective to treat an inflammatory condition of the GI tract of a compound having the following structure:

• where R1, R3, R4, and R5 are independently hydrogen or C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof;
• in admixture with a pharmaceutically acceptable diluent or carrier.

A pharmaceutical composition comprising an amount effective to treat an inflammatory condition of the GI tract of a compound having the following structure:

• where R1 is C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof;
• in admixture with a pharmaceutically acceptable diluent or carrier.

A pharmaceutical composition comprising an amount effective to treat an inflammatory condition of the GI tract of 5-(4-carboxymethyl phenylazo)-2-hydroxy-benzoic acid, or an ester or pharmacologically acceptable salt thereof;

• in admixture with a pharmaceutically acceptable diluent or carrier.

A pharmaceutical composition comprising an amount effective to treat an inflammatory condition of the GI tract of 5-[(4-(1-carboxy ethyl)-phenylazo]-2-hydroxy-benzoic acid, or an ester or pharmacologically acceptable salt thereof;

• in admixture with a pharmaceutically acceptable diluent or carrier.

A method of treating an inflammatory condition of the GI tract in a subject comprising administering to a subject in need of such treatment an effective amount of a compound having the following structure:

• where R1, R3, R4, and R5 are independently hydrogen or C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof.

A method of treating an inflammatory condition of the GI tract in a subject comprising administering to a subject in need of such treatment an effective amount of a compound having the following structure:

• where R1 is C1 to C4 alkyl;
• or an ester or pharmaceutically acceptable salt thereof.

A method of treating an inflammatory condition of the GI tract in a subject comprising administering to a subject in need of such treatment an effective amount of 5-(4-carboxymethyl phenylazo)-2-hydroxy-benzoic acid, or an ester or pharmacologically acceptable salt thereof.

A method of treating an inflammatory condition of the GI tract in a subject comprising administering to a subject in need of such treatment an effective amount of 5-[(4-(1-carboxy ethyl)-phenylazo]-2-hydroxy-benzoic acid, or an easter or pharmacologically acceptable thereof.